[Comment] Immune checkpoint inhibitors in malignant pleural mesothelioma

Malignant pleural mesothelioma is a tumour with a dismal prognosis and few effective therapeutic options. Most patients are treated upfront by chemotherapy containing pemetrexed and a platinum agent; unfortunately, nearly all patients progress during or after first-line therapy, and no standard second-line and further-line therapies are available. New treatment strategies are needed. Recently, immunotherapy by targeting of immune checkpoints such as CTLA-4 and PD-1 has changed the treatment framework of several tumours including melanoma, lung cancer, renal cancer, and urothelial neoplasms.

http://ift.tt/2oVhFOM